Achievements
-
.180Pathogen Boxes
shipped free of charge to scientists around the world to boost neglected diseases drug discovery
-
.8potential new medicines
in clinical development prioritizing treatment for vulnerable populations and supporting malaria eradication
-
.1stpotential new medicine
for relapsing malaria in more than 60 years, tafenoquine, completes phase III trials with GSK
Defeating malaria together
Featured resources
-
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
Jun 2018 -
Rapport de gestion 2017
MMV's Management Report in French
Jun 2018 -
Predicting transmission blocking potential of anti-malarial compounds in the Mosquito Feeding Assay using Plasmodium falciparum Male Gamete Inhibition Assay
May 2018
